|
GB9718972D0
(en)
|
1996-09-25 |
1997-11-12 |
Zeneca Ltd |
Chemical compounds
|
|
JP3522727B2
(ja)
|
1999-11-05 |
2004-04-26 |
アストラゼネカ アクチボラグ |
Ｖｅｇｆ阻害剤としてのキナゾリン誘導体
|
|
US6924285B2
(en)
|
2002-03-30 |
2005-08-02 |
Boehringer Ingelheim Pharma Gmbh & Co. |
Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, their use and process for preparing them
|
|
GB0309850D0
(en)
|
2003-04-30 |
2003-06-04 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
KR101126560B1
(ko)
|
2003-05-30 |
2012-04-05 |
도꾜 다이가꾸 |
약제 반응 예측 방법
|
|
GB0326459D0
(en)
|
2003-11-13 |
2003-12-17 |
Astrazeneca Ab |
Quinazoline derivatives
|
|
CA2565812C
(en)
|
2004-05-06 |
2012-03-13 |
Warner-Lambert Company Llc |
4-phenylamino-quinazolin-6-yl-amides
|
|
US7947676B2
(en)
|
2004-12-14 |
2011-05-24 |
Astrazeneca Ab |
Pyrazolo[3,4-d]pyrimidine compounds as antitumor agents
|
|
ATE488513T1
(de)
|
2005-09-20 |
2010-12-15 |
Astrazeneca Ab |
4-(1h-indazol-5-ylamino)chinazolinverbindungen als inhibitoren der erbb-rezeptortyrosinkinase zur behandlung von krebs
|
|
ES2530438T3
(es)
|
2006-09-12 |
2015-03-02 |
Genentech Inc |
Procedimientos y composiciones para el diagnóstico y tratamiento del cáncer de pulmón utilizando el gen de KIT o KDR como marcador genético
|
|
EP1921070A1
(de)
|
2006-11-10 |
2008-05-14 |
Boehringer Ingelheim Pharma GmbH & Co. KG |
Bicyclische Heterocyclen, diese Verbindungen enthaltende Arzneimittel, deren Verwendung und Verfahren zu ihrer Herstelllung
|
|
EA200901041A1
(ru)
|
2007-02-06 |
2010-02-26 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Бициклические гетероциклы, содержащие эти соединения лекарственные средства, их применение и способ их получения
|
|
TWI472339B
(zh)
|
2008-01-30 |
2015-02-11 |
Genentech Inc |
包含結合至ｈｅｒ２結構域ii之抗體及其酸性變異體的組合物
|
|
PL2245026T3
(pl)
|
2008-02-07 |
2013-01-31 |
Boehringer Ingelheim Int |
Spirocykliczne heterocykle, leki zawierające te związki, ich zastosowanie i sposób ich produkcji
|
|
MY183041A
(en)
|
2008-05-13 |
2021-02-08 |
Astrazeneca Ab |
Fumarate salt of 4- (3-chloro-2-fluoroanilino) -7-methoxy-6- {[1- (n-methylcarbamoylmethyl) piperidin- 4-yl] oxy}quinazoline
|
|
JP5539351B2
(ja)
|
2008-08-08 |
2014-07-02 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
シクロヘキシルオキシ置換ヘテロ環、これらの化合物を含有する医薬、およびそれらを生成するための方法
|
|
NZ594665A
(en)
|
2009-03-20 |
2013-08-30 |
Genentech Inc |
Bispecific anti-her antibodies
|
|
WO2011060246A2
(en)
|
2009-11-12 |
2011-05-19 |
Genentech, Inc. |
A method of promoting dendritic spine density
|
|
RU2012132278A
(ru)
|
2010-01-12 |
2014-02-20 |
Ф. Хоффманн-Ля Рош Аг |
Трициклические гетероциклические соединения, содержащие их композиции и способы их применения
|
|
PL2536748T3
(pl)
|
2010-02-18 |
2015-01-30 |
Genentech Inc |
Antagoniści neureguliny i ich zastosowanie w leczeniu nowotworu
|
|
CN102869359A
(zh)
|
2010-03-17 |
2013-01-09 |
弗·哈夫曼-拉罗切有限公司 |
咪唑并吡啶和嘌呤化合物、组合物和使用方法
|
|
CN103038643A
(zh)
|
2010-04-16 |
2013-04-10 |
基因泰克公司 |
作为pi3k/akt激酶途径抑制剂效能的预测性生物标记的foxo3a
|
|
ES2641916T3
(es)
|
2010-08-31 |
2017-11-14 |
Genentech, Inc. |
Biomarcadores y métodos de tratamiento
|
|
BR112013006016A2
(pt)
|
2010-09-15 |
2016-06-07 |
Hoffmann La Roche |
compostos de azabenzotiazol, composições e métodos de uso
|
|
CN103313987A
(zh)
|
2010-11-19 |
2013-09-18 |
弗·哈夫曼-拉罗切有限公司 |
吡唑并吡啶化合物、吡唑并吡啶化合物以及它们作为tyk2抑制剂的用途
|
|
WO2012085176A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Tricyclic pyrazinone compounds, compositions and methods of use thereof as janus kinase inhibitors
|
|
WO2013007765A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Fused tricyclic compounds for use as inhibitors of janus kinases
|
|
WO2013007768A1
(en)
|
2011-07-13 |
2013-01-17 |
F. Hoffmann-La Roche Ag |
Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors
|
|
CN103889976A
(zh)
|
2011-08-12 |
2014-06-25 |
弗·哈夫曼-拉罗切有限公司 |
吲唑化合物、组合物及使用方法
|
|
US20140363438A1
(en)
|
2011-08-17 |
2014-12-11 |
Genentech, Inc. |
Neuregulin antibodies and uses thereof
|
|
CN103827115A
(zh)
|
2011-09-20 |
2014-05-28 |
弗·哈夫曼-拉罗切有限公司 |
咪唑并吡啶化合物、组合物和使用方法
|
|
US20130195870A1
(en)
|
2011-11-30 |
2013-08-01 |
Genentech, Inc. |
ERBB3 Mutations In Cancer
|
|
EP2831115A1
(en)
|
2012-03-27 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Diagnosis and treatments relating to her3 inhibitors
|
|
KR20150118159A
(ko)
|
2013-02-22 |
2015-10-21 |
에프. 호프만-라 로슈 아게 |
암의 치료 방법 및 약물 내성의 예방 방법
|
|
US9925240B2
(en)
|
2013-03-06 |
2018-03-27 |
Genentech, Inc. |
Methods of treating and preventing cancer drug resistance
|
|
JP6660182B2
(ja)
|
2013-03-13 |
2020-03-11 |
ジェネンテック， インコーポレイテッド |
ピラゾロ化合物及びその使用
|
|
MX2015011606A
(es)
|
2013-03-14 |
2016-05-17 |
Genentech Inc |
Metodo para tratar cancer y prevenir resistencia a farmacos contra cancer.
|
|
WO2014152358A2
(en)
|
2013-03-14 |
2014-09-25 |
Genentech, Inc. |
Combinations of a mek inhibitor compound with an her3/egfr inhibitor compound and methods of use
|
|
RU2015143437A
(ru)
|
2013-03-15 |
2017-04-27 |
Дженентек, Инк. |
Способы лечения рака и предотвращения устойчивости к лекарственным препаратам для лечения рака
|
|
MX2016002794A
(es)
|
2013-09-05 |
2016-09-13 |
Genentech Inc |
Compuestos antiproliferativos.
|
|
TW201605857A
(zh)
|
2013-10-03 |
2016-02-16 |
赫孚孟拉羅股份公司 |
Ｃｄｋ８之醫療性抑制劑及其用途
|
|
CN105744954B
(zh)
|
2013-10-18 |
2021-03-05 |
豪夫迈·罗氏有限公司 |
抗rspo2和/或抗rspo3抗体及其用途
|
|
SG11201604995YA
(en)
|
2013-12-17 |
2016-07-28 |
Genentech Inc |
Methods of treating her2-positive cancers using pd-1 axis binding antagonists and anti-her2 antibodies
|
|
WO2015095423A2
(en)
|
2013-12-17 |
2015-06-25 |
Genentech, Inc. |
Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
|
|
EP3122900A1
(en)
|
2014-03-24 |
2017-02-01 |
F. Hoffmann-La Roche AG |
Cancer treatment with c-met antagonists and correlation of the latter with hgf expression
|
|
BR112016022345A2
(pt)
|
2014-03-31 |
2017-10-10 |
Genentech Inc |
terapia de combinação compreendendo agentes antiangiogênese e agonistas de ligação de ox40
|
|
RS59738B1
(sr)
|
2014-03-31 |
2020-02-28 |
Hoffmann La Roche |
Anti-ox40 antitela i postupci primene
|
|
JP6814730B2
(ja)
|
2014-09-05 |
2021-01-20 |
ジェネンテック， インコーポレイテッド |
治療用化合物およびその使用
|
|
EP3193866A1
(en)
|
2014-09-19 |
2017-07-26 |
Genentech, Inc. |
Use of cbp/ep300 and bet inhibitors for treatment of cancer
|
|
CN107912040B
(zh)
|
2014-10-10 |
2021-04-06 |
基因泰克公司 |
作为组蛋白脱甲基酶抑制剂的吡咯烷酰胺化合物
|
|
CA2966523A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Assays for detecting t cell immune subsets and methods of use thereof
|
|
WO2016073380A1
(en)
|
2014-11-03 |
2016-05-12 |
Genentech, Inc. |
Method and biomarkers for predicting efficacy and evaluation of an ox40 agonist treatment
|
|
CN107073126A
(zh)
|
2014-11-06 |
2017-08-18 |
豪夫迈·罗氏有限公司 |
包含ox40结合激动剂和tigit抑制剂的组合疗法
|
|
JP6639497B2
(ja)
|
2014-11-10 |
2020-02-05 |
ジェネンテック， インコーポレイテッド |
ブロモドメインインヒビターおよびその使用
|
|
MA40940A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
MA40943A
(fr)
|
2014-11-10 |
2017-09-19 |
Constellation Pharmaceuticals Inc |
Pyrrolopyridines substituées utilisées en tant qu'inhibiteurs de bromodomaines
|
|
MX2017006320A
(es)
|
2014-11-17 |
2017-08-10 |
Genentech Inc |
Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
|
|
US9763922B2
(en)
|
2014-11-27 |
2017-09-19 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
KR20170094165A
(ko)
|
2014-12-23 |
2017-08-17 |
제넨테크, 인크. |
화학요법-내성 암을 치료 및 진단하는 조성물 및 방법
|
|
WO2016109546A2
(en)
|
2014-12-30 |
2016-07-07 |
Genentech, Inc. |
Methods and compositions for prognosis and treatment of cancers
|
|
WO2016112284A1
(en)
|
2015-01-09 |
2016-07-14 |
Genentech, Inc. |
(piperidin-3-yl)(naphthalen-2-yl)methanone derivatives and related compounds as inhibitors of the histone demethylase kdm2b for the treatment of cancer
|
|
EP3242874B1
(en)
|
2015-01-09 |
2018-10-31 |
Genentech, Inc. |
Pyridazinone derivatives and their use in the treatment of cancer
|
|
EP3242875B1
(en)
|
2015-01-09 |
2022-02-23 |
Genentech, Inc. |
4,5-dihydroimidazole derivatives and their use as histone demethylase (kdm2b) inhibitors
|
|
EP3250571B1
(en)
|
2015-01-29 |
2022-11-30 |
Genentech, Inc. |
Therapeutic compounds and uses thereof
|
|
CN107438593B
(zh)
|
2015-01-30 |
2020-10-30 |
基因泰克公司 |
治疗化合物及其用途
|
|
MA41598A
(fr)
|
2015-02-25 |
2018-01-02 |
Constellation Pharmaceuticals Inc |
Composés thérapeutiques de pyridazine et leurs utilisations
|
|
CA2981183A1
(en)
|
2015-04-07 |
2016-10-13 |
Greg Lazar |
Antigen binding complex having agonistic activity and methods of use
|
|
KR20180008449A
(ko)
|
2015-05-12 |
2018-01-24 |
제넨테크, 인크. |
암에 대한 치료 및 진단 방법
|
|
CN107532217A
(zh)
|
2015-05-29 |
2018-01-02 |
豪夫迈·罗氏有限公司 |
用于癌症的治疗和诊断方法
|
|
JP2018518483A
(ja)
|
2015-06-08 |
2018-07-12 |
ジェネンテック， インコーポレイテッド |
抗ｏｘ４０抗体及びｐｄ−１軸結合アンタゴニストを使用して癌を治療する方法
|
|
JP2018521019A
(ja)
|
2015-06-08 |
2018-08-02 |
ジェネンテック， インコーポレイテッド |
抗ｏｘ４０抗体を使用して癌を治療する方法
|
|
CN116327953A
(zh)
|
2015-06-17 |
2023-06-27 |
豪夫迈·罗氏有限公司 |
使用pd-1轴结合拮抗剂和紫杉烷治疗局部晚期或转移性乳腺癌的方法
|
|
WO2017033019A1
(en)
|
2015-08-26 |
2017-03-02 |
Fundación Centro Nacional De Investigaciones Oncológicas Carlos Iii (Cnio) |
Condensed tricyclic compounds as protein kinase inhibitors
|
|
AU2016325610B2
(en)
|
2015-09-25 |
2019-10-10 |
Genentech, Inc. |
Anti-TIGIT antibodies and methods of use
|
|
WO2017106647A1
(en)
|
2015-12-16 |
2017-06-22 |
Genentech, Inc. |
Process for the preparation of tricyclic pi3k inhibitor compounds and methods for using the same for the treatment of cancer
|
|
AR107303A1
(es)
|
2016-01-08 |
2018-04-18 |
Hoffmann La Roche |
Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
|
|
EP4155415A1
(en)
|
2016-02-29 |
2023-03-29 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
WO2017180864A1
(en)
|
2016-04-14 |
2017-10-19 |
Genentech, Inc. |
Anti-rspo3 antibodies and methods of use
|
|
MX2018012493A
(es)
|
2016-04-15 |
2019-06-06 |
Genentech Inc |
Métodos para controlar y tratar el cáncer.
|
|
CA3019921A1
(en)
|
2016-04-15 |
2017-10-19 |
Genentech, Inc. |
Methods for monitoring and treating cancer
|
|
JP2019518426A
(ja)
|
2016-04-15 |
2019-07-04 |
ジェネンテック， インコーポレイテッド |
がんの診断及び治療方法
|
|
JP7160688B2
(ja)
|
2016-05-24 |
2022-10-25 |
ジェネンテック， インコーポレイテッド |
Ｃｂｐ／ｅｐ３００の複素環式インヒビターおよびがんの処置におけるそれらの使用
|
|
WO2017205538A1
(en)
|
2016-05-24 |
2017-11-30 |
Genentech, Inc. |
Pyrazolopyridine derivatives for the treatment of cancer
|
|
CN109312407A
(zh)
|
2016-06-08 |
2019-02-05 |
豪夫迈·罗氏有限公司 |
用于癌症的诊断和治疗方法
|
|
CN109963871A
(zh)
|
2016-08-05 |
2019-07-02 |
豪夫迈·罗氏有限公司 |
具有激动活性的多价及多表位抗体以及使用方法
|
|
JP7250674B2
(ja)
|
2016-08-08 |
2023-04-03 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
がんの治療及び診断方法
|
|
EP3523451A1
(en)
|
2016-10-06 |
2019-08-14 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP3532091A2
(en)
|
2016-10-29 |
2019-09-04 |
H. Hoffnabb-La Roche Ag |
Anti-mic antibidies and methods of use
|
|
ES2953595T3
(es)
|
2017-03-01 |
2023-11-14 |
Hoffmann La Roche |
Procedimientos diagnósticos y terapéuticos para el cáncer
|
|
CA3058279A1
(en)
|
2017-04-13 |
2018-10-18 |
F.Hoffmann-La Roche Ag |
An interleukin-2 immunoconjugate, a cd40 agonist, and optionally a pd-1 axis binding antagonist for use in methods of treating cancer
|
|
IL271888B2
(en)
|
2017-07-21 |
2024-09-01 |
Genentech Inc |
Therapeutic and diagnostic methods for cancer
|
|
KR20200041387A
(ko)
|
2017-09-08 |
2020-04-21 |
에프. 호프만-라 로슈 아게 |
암의 진단 및 치료 방법
|
|
EP3710001A4
(en)
|
2017-10-27 |
2021-07-14 |
University Of Virginia Patent Foundation |
COMPOUNDS AND PROCEDURES FOR REGULATING, LIMITING OR INHIBITING AVIL EXPRESSION
|
|
CA3077664A1
(en)
|
2017-11-06 |
2019-05-09 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
EP3797173A2
(en)
|
2018-05-21 |
2021-03-31 |
Nanostring Technologies, Inc. |
Molecular gene signatures and methods of using same
|
|
WO2019246557A1
(en)
|
2018-06-23 |
2019-12-26 |
Genentech, Inc. |
Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
|
|
TW202011991A
(zh)
|
2018-07-18 |
2020-04-01 |
美商建南德克公司 |
用pd-1軸結合拮抗劑、抗代謝劑及鉑劑治療肺癌之方法
|
|
JP7535500B2
(ja)
|
2018-09-03 |
2024-08-16 |
エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト |
Ｔｅａｄモジュレーターとして有用なカルボキサミドおよびスルホンアミド誘導体
|
|
CA3111401A1
(en)
|
2018-09-19 |
2020-03-26 |
Genentech, Inc. |
Therapeutic and diagnostic methods for bladder cancer
|
|
WO2020061349A1
(en)
|
2018-09-21 |
2020-03-26 |
Genentech, Inc. |
Diagnostic methods for triple-negative breast cancer
|
|
AU2019361983A1
(en)
|
2018-10-18 |
2021-05-20 |
Genentech, Inc. |
Diagnostic and therapeutic methods for sarcomatoid kidney cancer
|
|
EP3921443A1
(en)
|
2019-02-08 |
2021-12-15 |
F. Hoffmann-La Roche AG |
Diagnostic and therapeutic methods for cancer
|
|
SG11202108707WA
(en)
|
2019-02-27 |
2021-09-29 |
Epiaxis Therapeutics Pty Ltd |
Methods and agents for assessing t-cell function and predicting response to therapy
|
|
BR112021016923A2
(pt)
|
2019-02-27 |
2021-11-03 |
Genentech Inc |
Métodos para tratar um paciente com câncer hematológico, métodos para tratar um paciente com mm recidivante ou refratário, métodos para tratar um paciente tendo um lnh recidivante ou refratário e kits
|
|
WO2020223233A1
(en)
|
2019-04-30 |
2020-11-05 |
Genentech, Inc. |
Prognostic and therapeutic methods for colorectal cancer
|
|
CA3133821A1
(en)
|
2019-05-03 |
2020-11-12 |
Genentech, Inc. |
Methods of treating cancer with an anti-pd-l1 antibody
|
|
CN112300279A
(zh)
|
2019-07-26 |
2021-02-02 |
上海复宏汉霖生物技术股份有限公司 |
针对抗cd73抗体和变体的方法和组合物
|
|
PE20221449A1
(es)
|
2019-09-04 |
2022-09-21 |
Genentech Inc |
Agentes de union a cd8 y usos de los mismos
|
|
KR20220070237A
(ko)
|
2019-09-27 |
2022-05-30 |
제넨테크, 인크. |
항-tigit 및 항-pd-l1 길항제 항체를 이용한 치료를 위한 투약
|
|
EP4051674A1
(en)
|
2019-10-29 |
2022-09-07 |
F. Hoffmann-La Roche AG |
Bifunctional compounds for the treatment of cancer
|
|
IL292458A
(en)
|
2019-11-06 |
2022-06-01 |
Genentech Inc |
Diagnostic and treatment methods for the treatment of hematological cancer
|
|
CR20220207A
(es)
|
2019-11-13 |
2022-06-06 |
Genentech Inc |
Compuestos terapéuticos y métodos de uso
|
|
CR20230210A
(es)
|
2019-12-13 |
2023-06-14 |
Genentech Inc |
ANTICUERPOS ANTI-LY6G6D Y MÉTODOS DE USO (Divisional 2022-0330)
|
|
EP4076667A1
(en)
|
2019-12-20 |
2022-10-26 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2021194481A1
(en)
|
2020-03-24 |
2021-09-30 |
Genentech, Inc. |
Dosing for treatment with anti-tigit and anti-pd-l1 antagonist antibodies
|
|
IL294800A
(en)
|
2020-01-27 |
2022-09-01 |
Genentech Inc |
Methods of treating cancer with an antibody to an anti-ti antagonist
|
|
WO2021177980A1
(en)
|
2020-03-06 |
2021-09-10 |
Genentech, Inc. |
Combination therapy for cancer comprising pd-1 axis binding antagonist and il6 antagonist
|
|
WO2021202959A1
(en)
|
2020-04-03 |
2021-10-07 |
Genentech, Inc. |
Therapeutic and diagnostic methods for cancer
|
|
EP4143345A1
(en)
|
2020-04-28 |
2023-03-08 |
Genentech, Inc. |
Methods and compositions for non-small cell lung cancer immunotherapy
|
|
KR20230025691A
(ko)
|
2020-06-16 |
2023-02-22 |
제넨테크, 인크. |
삼중 음성 유방암을 치료하기 위한 방법과 조성물
|
|
EP4168118A1
(en)
|
2020-06-18 |
2023-04-26 |
Genentech, Inc. |
Treatment with anti-tigit antibodies and pd-1 axis binding antagonists
|
|
US11787775B2
(en)
|
2020-07-24 |
2023-10-17 |
Genentech, Inc. |
Therapeutic compounds and methods of use
|
|
CN116568824A
(zh)
|
2020-08-03 |
2023-08-08 |
基因泰克公司 |
淋巴瘤的诊断和治疗方法
|
|
EP4196612A1
(en)
|
2020-08-12 |
2023-06-21 |
Genentech, Inc. |
Diagnostic and therapeutic methods for cancer
|
|
EP4217071A1
(en)
|
2020-09-23 |
2023-08-02 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
JP2023544407A
(ja)
|
2020-10-05 |
2023-10-23 |
ジェネンテック， インコーポレイテッド |
抗ＦｃＲＨ５／抗ＣＤ３二重特異性抗体による処置のための投与
|
|
US20230107642A1
(en)
|
2020-12-18 |
2023-04-06 |
Erasca, Inc. |
Tricyclic pyridones and pyrimidones
|
|
WO2022171745A1
(en)
|
2021-02-12 |
2022-08-18 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
|
EP4347603A1
(en)
|
2021-05-25 |
2024-04-10 |
Erasca, Inc. |
Sulfur-containing heteroaromatic tricyclic kras inhibitors
|
|
US20240293558A1
(en)
|
2021-06-16 |
2024-09-05 |
Erasca, Inc. |
Kras inhibitor conjugates
|
|
EP4384522A1
(en)
|
2021-08-10 |
2024-06-19 |
Erasca, Inc. |
Selective kras inhibitors
|
|
EP4436969A2
(en)
|
2021-11-24 |
2024-10-02 |
Genentech, Inc. |
Bicyclic therapeutic compounds and methods of use in the treatment of cancer
|
|
EP4436957A1
(en)
|
2021-11-24 |
2024-10-02 |
Genentech, Inc. |
Therapeutic indazole compounds and methods of use in the treatment of cancer
|
|
AU2022450448A1
(en)
|
2022-04-01 |
2024-10-10 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023219613A1
(en)
|
2022-05-11 |
2023-11-16 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
WO2023240058A2
(en)
|
2022-06-07 |
2023-12-14 |
Genentech, Inc. |
Prognostic and therapeutic methods for cancer
|
|
WO2024015897A1
(en)
|
2022-07-13 |
2024-01-18 |
Genentech, Inc. |
Dosing for treatment with anti-fcrh5/anti-cd3 bispecific antibodies
|
|
TW202413433A
(zh)
|
2022-07-19 |
2024-04-01 |
美商建南德克公司 |
用抗ｆｃｒｈ５／抗ｃｄ３雙特異性抗體進行治療之給藥
|
|
TW202417439A
(zh)
|
2022-08-11 |
2024-05-01 |
瑞士商赫孚孟拉羅股份公司 |
雙環四氫噻吖呯衍生物
|
|
WO2024033458A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydroazepine derivatives
|
|
WO2024033389A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024033388A1
(en)
|
2022-08-11 |
2024-02-15 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
|
WO2024085242A2
(en)
|
2022-10-21 |
2024-04-25 |
Kawasaki Institute Of Industrial Promotion |
Non-fouling or super stealth vesicle
|
|
TW202426505A
(zh)
|
2022-10-25 |
2024-07-01 |
美商建南德克公司 |
癌症之治療及診斷方法
|
|
WO2024173842A1
(en)
|
2023-02-17 |
2024-08-22 |
Erasca, Inc. |
Kras inhibitors
|